Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive, and fatal interstitial lung disease characterized by irreversible fibrosis of lung parenchyma. Therapeutic progress has been slow, and one barrier sits upstream of the clinic: conventional preclinical models, rodent models in particular, reproduce only part of the pathology and physiology seen in human IPF. A model whose fibrosis resolves on its own cannot show whether a candidate changes the course of a disease that does not resolve.
To address this gap, Prisys Biotechnologies has established a clinically relevant non-human primate (NHP) model of Lung Fibrosis. By integrating medical imaging with functional respiratory assessment, the platform lets an anti-fibrotic programme measure structural and functional change in the same animal over time.
Interplay Between Immune Mechanisms and Pulmonary Pathology
The pathogenesis of IPF involves repetitive injury to alveolar epithelial cells together with dysregulation of the local immune microenvironment. Immune-mediated processes contribute to fibrotic progression, and the clinical overlap is visible in patients: interstitial lung disease and pulmonary fibrosis are common complications of systemic autoimmune disorders such as rheumatoid arthritis, which points to a shared route between immune dysfunction and fibrotic remodeling.
A model built for this disease therefore has to carry both components. A fibrosis-only readout hides the immune contribution, and an inflammation-only model never reaches the remodeling stage that a candidate is meant to reverse.
Prisys Biotechnologies has developed a bleomycin-induced pulmonary fibrosis model in cynomolgus monkeys through targeted intratracheal administration (single-lobe or multi-lobe delivery). This approach induces chronic and progressive interstitial pneumonia with pathological features closely resembling human IPF, including fibrotic band formation and honeycomb-like structural remodeling. The model has been applied in NHP Pharmacology studies of candidate anti-fibrotic agents.
Advancing Structural Assessment: Quantitative CT Imaging and Lung Lesion Analysis
Accurate and objective quantification of fibrotic burden is a critical requirement in IPF drug development. High-resolution computed tomography (CT) plays a central role in non-invasive assessment of lung structure and disease progression, and it is the modality a clinical team will also use when the programme reaches patients.
Prisys Biotechnologies' clinical research platform is equipped with Clinical Imaging systems capable of high-resolution thoracic scans in large animal models. The platform also carries dedicated post-processing software, including CT-based lung nodule analysis and emphysema quantification tools.
Three-dimensional (3D) imaging reconstruction supports semi-automated or fully automated segmentation of airways, specific lung lobes, and fibrotic lesions. From those segmentations, fibrosis can be quantified by volume and followed longitudinally, either as the disease progresses or as a treatment takes effect.
Histopathology, by contrast, is terminal and samples a small region of the lung, so it describes one time point in one place. CT-based 3D imaging reads the same animal repeatedly and without surgery, which improves data continuity, removes the variability that comes from comparing different animals at different stages, and makes the result easier to line up with clinical practice.
Aligning with Clinical Endpoints: Comprehensive Pulmonary Function Testing (PFT)
Imaging describes structure. What determines outcome for a patient is the progressive decline of respiratory function, so functional endpoints are required to demonstrate therapeutic benefit at all.
Prisys Biotechnologies integrates pulmonary function testing (PFT) into the same preclinical framework. Cynomolgus monkeys undergo longitudinal Respirology monitoring at baseline and at multiple post-induction time points.
Key physiological parameters, including lung resistance and pulmonary compliance, are recorded and quantified. Impairment and recovery can therefore be evaluated as they happen, rather than reconstructed from terminal samples afterwards.
Read together, the structural and functional datasets form an imaging-anchored Pharmacodynamics (PD) readout that can be set beside exposure data from the same animals. That pairing is what makes a preclinical result usable for dose selection rather than only for ranking compounds.
The combination of "quantitative CT imaging" and "dynamic pulmonary function assessment" establishes an evaluation system that bridges anatomical and physiological endpoints. A candidate that shrinks the fibrotic lesion without improving compliance presents a different profile from one that improves compliance at stable lesion volume, and the two profiles support different decisions about dose and duration. Such an integrated approach closely aligns with clinical trial standards and strengthens the predictive value of preclinical findings.
Conclusion
Effective therapies for IPF and related pulmonary diseases require models and evaluation systems with high translational relevance. Prisys Biotechnologies addresses this need through a large animal translational platform that integrates NHP disease modeling, CT imaging analysis, and multidimensional pulmonary function assessment. The IPF work sits within Prisys' Nonhuman Primate Disease Models, alongside the respiratory and immunology programmes that share the same imaging and functional workflow.
This end-to-end setup provides objective, quantitative, and clinically meaningful data to support global drug development pipelines, and it shortens the distance between a preclinical result and the decision it is meant to inform.
Frequently Asked Questions (FAQ)
Q: Why is drug development for Idiopathic Pulmonary Fibrosis (IPF) particularly challenging?
A: IPF is a multifactorial disease involving epithelial injury, aberrant wound healing, immune dysregulation, and progressive fibrotic remodeling. Traditional preclinical models, especially rodent models, often fail to replicate the chronic progression, spatial heterogeneity, and functional decline observed in human IPF. That gap limits the predictive value of preclinical efficacy data and contributes to high clinical failure rates.
Q: What advantages do non-human primate (NHP) models offer in IPF research?
A: NHP models, particularly cynomolgus monkeys, provide closer anatomical, physiological, and immunological similarity to humans compared to rodents, which raises the translational relevance of findings in studies involving immune modulation and lung function. The bleomycin-induced NHP model developed by Prisys replicates chronic, progressive fibrosis with key pathological features such as fibrotic bands and honeycomb-like remodeling.
Q: How does the bleomycin-induced NHP model improve translational predictability?
A: Unlike acute or self-resolving rodent models, the NHP model supports sustained and progressive fibrosis. Targeted intratracheal delivery (single-lobe or multi-lobe) allows controlled induction of localized or diffuse disease, which better mimics clinical heterogeneity and supports evaluation of drug efficacy, dose-response relationships, and disease-modifying potential.
Q: Why is quantitative CT imaging critical in IPF preclinical studies?
A: High-resolution CT imaging provides a non-invasive and longitudinal method to assess lung structure and fibrotic burden. Through 3D reconstruction and segmentation, researchers can quantify lesion volume, monitor disease progression, and evaluate treatment response over time. This approach overcomes the limitations of traditional histopathology, which is terminal and provides only snapshot-based data.
Q: What specific capabilities does Prisys offer in CT-based lung analysis?
A: Prisys integrates imaging hardware with dedicated post-processing software, including lung nodule analysis and emphysema quantification tools. The platform supports semi-automated and automated segmentation of lung lobes, airways, and fibrotic regions, which enables volumetric measurements and percentage change analysis in longitudinal studies.
